United Therapeutics Corp (NAS:UTHR)
$ 265.91 4.96 (1.9%) Market Cap: 11.80 Bil Enterprise Value: 9.48 Bil PE Ratio: 12.58 PB Ratio: 2.20 GF Score: 89/100

Q2 2019 United Therapeutics Corp Earnings Call Transcript

Jul 31, 2019 / 01:00PM GMT
Release Date Price: $79.24 (-0.36%)
Operator

Good morning, and welcome to the United Therapeutics Corporation Second Quarter 2019 Earnings Call. My name is Michelle, and I will be your conference operator today. (Operator Instructions)

I will now turn the conference over to Mr. James Edgemond, Chief Financial Officer of United Therapeutics.

James C. Edgemond
United Therapeutics Corporation - CFO & Treasurer

Thank you, Michelle, and good morning, everyone. It is my pleasure to welcome you to the United Therapeutics Corporation's Second Quarter 2019 Earnings Call. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; and Mr. Michael Benkowitz, our President and Chief Operating Officer. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Form 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot